If your organization is wrestling with this question, we would like to introduce you to Viral Sign®!
Viral Sign screening science is distinguished by the technology’s ability to identify the presence of virus, including COVID-19, in individuals prior to the onset of fever.
Viral Sign is advanced screening science designed to provide efficient and effective screening of populations.
Viral Sign applies advanced screening science to help healthcare providers, manufacturers, and other enterprise organizations create site-safe work environments for employees, customers, and visitors. The artificial intelligence in Viral Sign equips client organizations to detect afebrile individuals infected with COVID-19, and other respiratory infectious diseases. Viral Sign represents an important tool to help mitigate the transmission of ILI in high-risk settings.
Viral Sign has been deployed into work sites in the U.S., South America, Middle East, and Europe. Since March of 2020, over 500,000 screens have been conducted using Viral Sign.
The Viral Sign algorithm leverages the power of infrared imaging to produce a comprehensive thermal signature of the face. In real-time, Viral Sign assesses the thermal signature across the regions of interest in the face to identify patterns consistent with early, presymptomatic influenza-like illness (ILI). The total time required for Viral Sign to capture the infrared image, evaluate the thermal signature, and indicate the suspicion of virus is approximately two seconds.
Viral Sign does not make a medical diagnosis. A medical diagnosis must be made by a licensed healthcare professional.
Precision
96% accurate with greater sensitivity for the detection of fever and prefebrile state. Superior to solutions that detect only point temperature (point thermometers) or a single mass temperature (thermal cameras).
Safety
Viral Sign eliminates close contact between the evaluator and the individual being screened.
Speed
Processing speed (<2 seconds) allows the screening process with Viral Sign to be workflow neutral, enabling individuals to get to the job site or destination quickly.
Alarms
Visual and audible alerts inform the evaluator when virus is suspected in an individual. The audible alerts may be turned off when appropriate for the setting.
Comprehensive
A comprehensive thermal signature produces a result that identifies where there is high suspicion for the presymptomatic presence of virus.
AI-Driven Results
The artificial intelligence in Viral Sign produces a result (Okay, Evaluate, or Risk) that does not require interpretation by the evaluator. The evaluator is not required to be a medical professional.
Select Clients
Suitable for:
Viral Sign™ can be used in any environment, according to international epidemiological protocols.
Viral Sign™ is based on the Intelligent Infrared Image Screening Protocol for Coronavirus COVID-19 and follows international ISO standards.
Public transport
Airports
Hospitals
Companies
Smart
Advanced algorithm, using multiple factors for greater accuracy in the classification of risks of public health problems.
Trusted
Supported by a medical team with 20 years of experience in the area of Thermology and Thermography.
Protocol Compliant
Application of the most current international epidemiological and logistical protocols.
Collaborative
Compatible with and assistive to laboratory tests, healthcare facilities, and locations for disease assessment and control.
How does Viral Sign integrate into arrival workflow?
Incorporating Viral Sign into the onboarding process for employees, customers, and guest can be executed with minimal adjustments to workflow. The process requires three steps which can be executed in under three seconds.
Step 1
Individuals are monitored remotely as they pass through the checkpoint for the facility (airports, ports, business entrances, corporations, schools, etc.).
The set-up at the point of screening includes an infrared camera, a laptop tethered directly to the camera, a camera stand, point of screening floor guides (“Stand Here”), and a 21-inch monitor (to permit those being screened to see their result in real-time).
Step 2
Viral Sign delivers a visible result for to communicate the individuals status: Okay, Evaluate, or Risk. An audible alert can be turned on to bring increased awareness to screens that result in Evaluate or Risk.
The monitor (or individual examining results) is not required to interpret the visual image and is not required to be a medical professional. Interpretation is executed by the artificial intelligence in Viral Sign.
Step 3
Individuals identified as “suspicious for the presence of virus”, indicated by the Evaluate or Risk result, are separated from the queue for a follow-up assessment with health professionals or support personnel per the organization’s protocol.
Viral Sign is superior to the best thermography result published by Singapore-based researchers during the SARS-2003 outbreak.
SARS-2003
Viral Sign™
False negatives: The great challenge of this pandemic.
Less than 30% of people have a temperature higher than 37.8ºC in the first 5 days after becoming infected with COVID-19. As a result, there is great risk for a large number of false negatives.
Symptomatic screening with a single point body temperature permits individuals who are “false negatives”, infected but without fever, to enter factories, healthcare facilities, schools, government buildings, and other centers where people gather.
The virus thrives on false negatives.
Liu T, Zhang J, Yang Y, Zhang L, Ma H, Li Z, et al. The potential role of IL-6 in monitoring coronavirus disease 2019. medRxiv. 2020.
How does Viral Sign differ from point (thermometer) and mass temperature (thermal camera) assessment?
Both point thermometers and thermal cameras are based on a single maximum temperature point.
This greatly diminishes the efficacy of these screening methods due to distance, temperature, and ambient humidity. The appropriateness of the target, or area where the device is pointed, and the steadiness of the device can alter the temperature result. And, or course, the virus may be present, but not symptomatic (with fever).
Point clinical thermometer temperature assessment evaluates a single point on the forehead, ear or wrist.The weaknesses of point thermometer measurement include
-
Great variability in readings and lower accuracy,
-
Exposes the operator to risk of infection from the individuals the operator encounters for screening,
-
Exposes those being screened to a person (the operator) who may be infected.
Thermal cameras cannot identify the presence of virus prior to the onset of fever.
The measurement of only elevated body temperature, based on fixed values such as 37.5 degrees Celsius or 99.6 degrees Fahrenheit, is not enough to track cases of people infected with COVID-19.
Despite receiving an image representing several temperature points, thermal cameras rely only on a single point of maximum temperature. This is similar in many respects to the use of point temperature thermometers.
In addition, thermal cameras do not limit the analysis of temperature to the maximum temperature point of human skin. The thermal camera can randomly retrieve temperature measurements outside the human body.
The eyes are a region that can get more or less moist due to tears. Tearing in the eyes does not correlate with fever.
Vascular diseases or lesions in this region of the face can hinder the analysis also based on a single point.
The maximum temperature of the body surface is not always the most effective way to know if the person is infected by the new coronavirus (COVID19).
Number of people infected with eye temperature below 37.2 C (no fever).
Body temperature measurement of 313 people.
Conventional Thermography
35% of people with fever had eye temperature below 37.2C.
Identified only 31 people with fever
The problem with traditional thermography is that people can be contaminated even without fever.
Viral Sign™
All people (with and without fever) were screened correctly by ViralSign™, regardless of eye temperature.
Correct identification of the 48 people infected
We identify people at risk of contaminating others regardless of whether they have fever/temperature high or not.
Ng, E. Y-K. and Kee E.C., “Fever Mass Screening Tool for Infectious Diseases Outbreak: Integrated artificial intelligence with bio-statistical approach in thermogram analysis”, Medical Infrared Imaging, Biomedical Engineering Handbook, ISBN-0-8493-9027-3, CRC Press, 2008, FL, USA, Editor: Nicholas Diakides and Joseph D. Bronzino, Chp. 16, pp. 1-19.
Meet the Team
The Viral Sign team is defined by a shared commitment to clients, to communities, and to continuous pursuit of insight.
Barry Hix, President and Chief Executive Officer
Barry brings a diverse set of insights to chief executive role at Viral Sign as a result of his experience in the pharmaceutical, healthcare delivery, medical device, and healthcare technology industries. As a commercial leader, Barry has led venture funded, early commercial stage entities as well as private equity-owned organizations with more than $200 million in annual sales. This experience has required him to lead organizations into and through early commercial stage activity, asset acquisition, mergers, force expansion, and force and asset restructuring.
Barry has held board positions with Allina Healthcare and Cadence Biomedical. He has served as speaker at national conferences including the Federation of American Health Systems, the Global Business Forum on Health, and HIMMS.
Hix holds a bachelor’s degree in industrial management from the Georgia Institute of Technology, a master’s degree in marketing from Georgia State University, and a master’s degree in public health from Emory University.
https://www.linkedin.com/in/barryhix/
Bill Dornbach, Chief Operating Officer
Bill Dornbach has extensive background in strategic planning, product launch, and brand development for both reimbursed and consumer-focused healthcare products. For Viral Sign, Bill’s skill set will be deployed across a number of strategic areas, including operations, product development, marketing operations, sales support, client services, and business development.
Bill’s operational history extends across consumer engagement, enterprise transition, including preparing for private equity investment, pre-merger preparation, and post-merger integration of marketing, sales, sales support, and internal operations. Bill’s operation and analytical expertise, has led to the launch of more than 26 companies and products, along with multiple client solution patents, including technology-enabled CRM solutions.
Bill has held several board positions in both the healthcare and technology industries.
https://www.linkedin.com/in/bill-dornbach-2a5471/
Bill Dornbach, Chief Operating Officer
Bill Dornbach has extensive background in strategic planning, product launch, and brand development for both reimbursed and consumer-focused healthcare products. For Viral Sign, Bill’s skill set will be deployed across a number of strategic areas, including operations, product development, marketing operations, sales support, client services, and business development.
Bill’s operational history extends across consumer engagement, enterprise transition, including preparing for private equity investment, pre-merger preparation, and post-merger integration of marketing, sales, sales support, and internal operations. Bill’s operation and analytical expertise, has led to the launch of more than 26 companies and products, along with multiple client solution patents, including technology-enabled CRM solutions.
Bill has held several board positions in both the healthcare and technology industries.
https://www.linkedin.com/in/bill-dornbach-2a5471/
Bill Dornbach, Chief Operating Officer
Bill Dornbach has extensive background in strategic planning, product launch, and brand development for both reimbursed and consumer-focused healthcare products. For Viral Sign, Bill’s skill set will be deployed across a number of strategic areas, including operations, product development, marketing operations, sales support, client services, and business development.
Bill’s operational history extends across consumer engagement, enterprise transition, including preparing for private equity investment, pre-merger preparation, and post-merger integration of marketing, sales, sales support, and internal operations. Bill’s operation and analytical expertise, has led to the launch of more than 26 companies and products, along with multiple client solution patents, including technology-enabled CRM solutions.
Bill has held several board positions in both the healthcare and technology industries.
https://www.linkedin.com/in/bill-dornbach-2a5471/
Bill Dornbach, Chief Operating Officer
Bill Dornbach has extensive background in strategic planning, product launch, and brand development for both reimbursed and consumer-focused healthcare products. For Viral Sign, Bill’s skill set will be deployed across a number of strategic areas, including operations, product development, marketing operations, sales support, client services, and business development.
Bill’s operational history extends across consumer engagement, enterprise transition, including preparing for private equity investment, pre-merger preparation, and post-merger integration of marketing, sales, sales support, and internal operations. Bill’s operation and analytical expertise, has led to the launch of more than 26 companies and products, along with multiple client solution patents, including technology-enabled CRM solutions.
Bill has held several board positions in both the healthcare and technology industries.
https://www.linkedin.com/in/bill-dornbach-2a5471/
Call us at (833) 99-VIRAL.
Or, use the form below to request follow-up from a member of our team.
The priority is saving lives.
This product aims to support mass screening, and is not intended for isolated or definitive diagnosis. Viral Sign does not replace the medical judgment of a healthcare professional. A positive result should be followed by a diagnostic examination conducted by a licensed healthcare professional. Regardless of negative outcome, all care must be maintained to protect oneself.
